Bullish
Johnson & Johnson's RYBREVANT FASPRO™ shows 56% response rate in head and neck cancer trial.
Johnson & Johnson's investigational treatment, RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), demonstrated a 56% overall response rate in a Phase 1b/2 study for first-line recurrent or metastatic head and neck squamous cell carcinoma. This promising result suggests potential for improved outcomes in this patient population.
Key points
- RYBREVANT FASPRO™ achieves 56% overall response rate in head and neck cancer trial.
- FDA approves RYBREVANT FASPRO™ for monthly dosing, enhancing patient convenience.
- Johnson & Johnson invests over $1 billion to strengthen U.S. vision manufacturing in Jacksonville, Florida.
Sources
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancerJohnson & Johnson · February 19, 2026
- FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a monthNasdaq · February 17, 2026
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, FloridaJohnson & Johnson · June 15, 2026
AI-generated from public news sources. Not financial advice.
